TCTR20160921001Enrolling By Invitation1 期
Phase I/II Pilot Study of Maximum Tolerated Dose of Chimeric Antigen Receptor (CAR) - modified T-cell lymphocytes against CD19 antigen in patients with relapsed/refractory B cell leukemia
TCELS0 个研究点目标入组 15 人开始时间: 2016年9月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 Years 至 25 Years（—）
- 性别
- All
入选标准
- •1. Age less than 25 years
- •2. Treated at Ramathibodi Hospital
- •3. Diagnosed with relapsed/refractory B-cell leukemia with expressing CD19
- •4. Bilirubin less than 4.5mg/dL
- •5. AST less than 150 U/dL
- •6. Glomerular filtration rate 50 or more than 50ml/1.73m2/min
- •7. Available stem cell donor in family members
- •8. No pregnancy
- •9. Signed informed consent
排除标准
- •Denied to be enrolled in the study
研究者
相似试验
Enrolling By Invitation
1 期
K cells for the treatment of neuroblastomaHigh risk neuroblastomaNK cellNeuroblastomaTCTR20160918001TCELS15
已完成
1 期
Phase I trial of carboplatin in combination with irinotecan and paclitaxel split-dosed on days 1 and 8ACTRN12609000790246Hellenic Cooperative Oncology Group20
进行中（未招募）
1 期
A Phase I/II study of WX-554 in solid tumoursPatients with advanced, metastatic and/or progressive solid tumours for whom there is no effective standard therapy available.MedDRA version: 14.1 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 100000004864EUCTR2011-003408-19-GBWILEX AG50
进行中（未招募）
1 期
未命名试验Acute graft versus host disease after allogeneic hematopoietic stem cell transplantation or donor lymphocyte infusionMedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2017-002715-34-ITADIENNE SA50
进行中（未招募）
1 期
A Clinical Study to investigate the Safety and Tolerability of VAL201 (new trial drug) in Patients with Locally Advanced or Metastatic (cancer cells which spreads from one part of the body to another) Prostate Cancer and Other Advanced Solid Tumours.EUCTR2013-004009-25-GBValiRx plc81